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Tobacco smoking is a major threat to health. There is no doubt about the need to promote and 
support cessation at every opportunity. Smoking has a clear role in rheumatoid arthritis, but what 
evidence is there that the same relationship exists in spondyloarthritis? In this review, we examine 
(the less cited) paradoxes and contradictions in existing axial spondyloarthritis (axSpA) and psoriatic 
arthritis (PsA) literature; for example, smoking appears to be ‘protective’ for some axSpA 
manifestations. We also highlight findings from higher quality evidence: smoking is associated with 
increased risk of PsA and the risk of psoriasis in axSpA. The relationship between smoking and SpA is 
far from simple. Our aim is to highlight the harms of smoking in SpA and bring attention to 
inconsistencies in the literature to inform further research. 
 
Keywords: axial spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, extra-articular 
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Key messages: 
1) Smoking cessation should be supported at every opportunity given the harms to general 
health. 
2) There are many inconsistencies in the literature regarding the impact of smoking on 
spondyloarthritis. 










Tobacco smoking is one of the greatest threats to health in our time. The World Health Organization 
estimates that there are 7 million deaths per year as a direct result of tobacco use and a further 1.2 
million through second-hand smoke [1]. In the UK, approximately 17% of all deaths in the past 10 
years have been attributed to smoking [2]. Its direct causal contribution to morbidity is also clear, 
such as cardiorespiratory and malignant diseases. The message to all healthcare professionals is 
therefore clear: support smokers to quit at every opportunity. In rheumatology, there is consistent 
evidence that smoking has a detrimental role in the patho-aetiology of rheumatoid arthritis (RA) 
through its interaction with citrullination and antibody formation [3]. The role of smoking in 
spondyloarthritis, however, is less clear. 
 
Does it matter? Do we need another reason to tell smokers to stop smoking? Investing in high-quality 
research on this topic is important for several reasons: First, examining smoking’s association with RA 
led to improved understanding of the disease; if smoking has a role in SpA the same goal may be 
pursued. Second, SpA patients may be more likely to quit if they know that smoking not only could 
reduce longevity but also their quality of life, for example, through extra-articular disease 
manifestations or functional impairment. Lack of awareness about the link between smoking and RA 
was identified as an important barrier to smoking cessation in RA patients [4]. Third, allocating 
resources for additional targeted smoking cessation may be cost-effective if it improves response to 
expensive biologic therapies. Finally, research on this topic is important because, as we will see, 
there are lessons to be learnt for future observational research. In this review, we focus discussion on 
two main members of the SpA family: axial SpA (axSpA) and psoriatic arthritis (PsA). Our aim is not to 
question the known harms of smoking or the need for smoking cessation, but instead to collate 
existing evidence in SpA to inform clinical practice and highlight research needs. As the reader will 





How big a problem is smoking in SpA? 
 
In 2018, 15% of UK adults were classified as current smokers [2]. The prevalence is much higher in 
SpA cohorts: 29% in the international ASAS-COMOSPA study and 24% in the BSR biologics register for 
AS (BSRBR-AS, which recruits axSpA patients). This does not necessarily implicate a causal role. 
Two-thirds of AS patients in the UK are managed in primary care; hospital-based research samples 
are likely taken from those with more severe disease. Young adults – who form the majority of SpA 
cohorts – also have the highest prevalence of smoking: UK adults aged 25 to 34 were much more 
likely to smoke than those aged 65 and over (prevalence 19 vs 8%) [2]. 
 
Potential mechanisms for smoking to impact on SpA? 
 
Cigarette smoke is a cocktail of thousands of chemical components, each can directly influence the 
immune system or indirectly through, for example, modifying the oral microbiome [5,6]. The overall 
effects include increased free radical burden and auto-reactive B cell activity, decreased 
neutrophil/T-cell activity and decreased cytokine production [6]. Smoking has a dose-response 
relationship with RA risk, severity and ACPA positivity. Similar associations have been described for 
other autoimmune disorders such as SLE and Graves’ disease [6,7]. Smoking’s role in diseases 
towards the auto-inflammatory end of the spectrum (less female preponderance and autoantibodies, 
greater implication for mechanical stress, etc [8]) is less clear. Current smokers have lower risk and 
severity of ulcerative colitis, but the opposite is true in Crohn’s disease [6]. In Behçet’s disease – a 
condition patho-mechanistically related to SpA [9] - current smokers have fewer oral aphthae and 
cessation may aggravate oral disease [10,11]. 
 
To make matters more complex, many factors related to smoking may also influence both incidence 
and severity of SpA; smoking is associated with manual occupations, unemployment, lower physical 
activity, lower educational attainment, BMI, and other lifestyle and socioeconomic factors [2,12–15]. 




Smoking vs incidence and onset of SpA 
 
This and the following sections are supported by systematic literature searches and, where possible, 
meta-analyses. Detailed methods (search strategy, statistics) and results (flowchart, summary of 
studies found, forest and funnel plots) are available in online supplementary materials. 
 
Smoking is often said to increase the risk of axSpA. The only study is from the Norwegian population 
case-control study that reported twice the odds of self-reported AS (n=107) in current compared to 
never smokers [16]. Although the authors tried to confirm diagnoses where possible, the cohort was 
atypical: there were fewer males than females (0.7:1). The validity of self-reported diagnosis is 
uncertain: a high number of self-reported cases (n=174) in the first wave of the study no longer 
reported AS in the second, and the incidence of AS was much higher than other studies. Past 
smoking and pack years did not demonstrate a dose-response association with incidence. Lastly, the 
independent causal role of smoking is uncertain, since many important confounders listed above 
were unaccounted for. 
 
Smoking has also been associated with earlier onset of inflammatory back pain. In 654 early axSpA 
patients from the DESIR cohort (63% HLA-B27 positive, 29% meeting modified New York criteria), 
ever smokers reported symptoms 1.5 years earlier than never smokers (P=0.04) [17]. A similar sized 
difference was seen for age at onset of peripheral arthritis and enthesitis in this study, although not 
statistically significant. No information on pack-years was available and analyses were not adjusted 
for important confounders, except alcohol status. Significant differences in age at symptom onset 
were not observed in 4 other studies identified through literature search [12,18–20]. The weighted 
mean difference between ever and never smokers in all 5 studies was 0.1 years (Table 1). Differences 
between current and non-current smokers was more consistent, but not statistically or clinically 
significant. An independent role of smoking in axSpA onset is unsupported by consistent evidence 
and subject to citation bias. 
 
The evidence for psoriatic arthritis (PsA) is more convincing. Compared to never smokers, current 
smokers had 27%, and past smokers 32%, higher risk of PsA than the UK general population (>6 
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million people in The Health Improvement Network) [21]. Clearer dose-response associations were 
shown in >90,000 females from the US Nurses’ Health Study II: current (relative risk (RR) 3.1) and 
past smokers (RR 1.5) had higher risk than never smokers; risk also increased monotonically with 
pack-year exposure [22]. Both studies adjusted for BMI and alcohol intake, while the latter also 
accounted for physical activity; neither included socioeconomic status. These findings are consistent 
with the increased risk of psoriasis among smokers [23]. Interestingly, the relationship between 
smoking and PsA is reversed when restricted to only those with psoriasis (i.e., smoking appears 
‘protective’ for joint disease) [21,24]; a methodological artefact – collider bias – may explain this and 
several other paradoxes, as we will discuss later. 
 
Disease mechanisms at the skin, joints, axial skeleton and other sites in SpA are likely to differ, as 
suggested by differential efficacy of anti-cytokine therapies [25]. The concordant effects of smoking 
in psoriasis and PsA, but not axSpA, could contribute to improved understanding of their pathology. 
 
Smoking vs disease severity: cross-sectional studies 
 
We identified 18 cross-sectional studies comparing axSpA disease severity according to smoking 
status and one PsA study [12,17–20,26–38] (Supplementary Table S1). (We use ‘disease severity’ to 
encompass disease activity and other outcomes such as function and quality of life.) When 
comparisons were meta-analyzed, ever-smokers had significantly higher BASDAI, BASFI, spinal pain 
and poorer quality of life than never smokers (table 1). Effect sizes were larger when comparing 
current and non-current (i.e., past and never) smokers. In a recent analysis of the BSRBR-AS, these 
differences remained significant after adjusting for education, deprivation, BMI, comorbidities and 
alcohol status [12]; smokers in this study also reported worse sleep, fatigue and mental health, but 
not ESR or CRP. Meta-analysis showed no clinically meaningful or statistically significant difference in 
ESR according to smoking status. Current smokers had 2mg/dl higher CRP on average than 
non-current smokers. 
 
Only one PsA study met our inclusion criteria [38]. In 1185 Swedish survey respondents with PsA (59% 
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responded), ever smokers reported poorer quality of life (0.04 units in EQ-5D), global health, pain 
and fatigue (by 0.3 to 0.4 units out of 10) than never smokers, but not HAQ [38]. We excluded 
baseline comparisons from longitudinal studies of biologic-treated cohorts because differences were 
masked by their already high disease activity [39,40].  
 
There is consistent evidence that SpA severity is associated with smoking. But as with all 
cross-sectional studies, the direction of causation cannot be determined; for this we turn to 
longitudinal designs. 
 
Table 1. Summary of meta-analysis results presented as weighted mean difference (95% 
confidence interval). 
 Ever vs never smokers Current vs non-current smokers 
Age of symptom 
onset, years 
0.07 (-1.01, 1.14)  n=5 
I2=55% 
-0.63 (-1.34, 0.07) n=4 
I2=0% 
BASDAI 0.58 (0.35, 0.81)  n=10 
I2=61% 
0.91 (0.61, 1.20) n=9 
I2=70% 
BASFI 0.83 (0.20, 1.47)  n=3 
I2=81% 
0.81 (0.34, 1.27) n=8 
I2=87% 
Spinal pain 0.69 (0.37, 1.01) n=4 
I2=56% 
0.83 (0.20, 1.47) n=3 
I2=81% 
CRP, mg/dl 1.45 (-0.08, 2.99) n=8 
I2=65% 
1.93 (0.47, 3.38) n=5 
I2=0% 
ESR, mm/hr 0.51 (-1.76, 2.78) n=8 
I2=65% 
1.11 (-1.46, 3.68) n=6 
I2=54% 
ASQoL n/a n/a 2.03 (-0.21, 4.26) n=5 
I2=93% 
n=number of studies; I2, measure of estimate heterogeneity; ASQoL, AS quality of life 
questionnaire. Estimates were from random-effects models; detailed methodology and forest 
plots are shown in supplementary materials. 
 
Smoking vs disease severity: longitudinal studies 
 
Six longitudinal studies specifically examined the role of smoking in SpA (5 axSpA, 1 PsA), while 16 
included smoking in their study of other exposures or predictors (8 axSpA, 4 SpA, 4 PsA) ([41–62] 
summarized in Supplementary Table S2). All except 4 examined response to treatment. Results were 
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too heterogeneous to perform meta-analysis. We focus discussion on studies of treatment response 
with regard to three outcome types: 1) binary response criteria (reaching a target, e.g., ASDAS<1.3) 
at a specific time point, 2) continuous change over time (e.g. ∆BASDAI), and 3) risk of treatment 
discontinuation (time-to-event analysis). 
 
There is consistent evidence that smokers have lower odds of binary response than non-smokers in 
unadjusted analyses (Supplementary Table S1). Another consistent finding is that statistically 
significant effects generally became smaller and non-significant after adjusting for confounders. 
Other smoking-related factors clearly also influence treatment response. Only 5 out of 11 axSpA (0 of 
3 PsA) studies reported significant adjusted odds ratios. Current smokers with AS had 47% lower 
odds of BASDAI50/2 (50% or 2-unit reduction) in the DANBIO registry [58]. In a UK axSpA cohort, 
current smokers had 65% lower odds of achieving BASDAI<3 at 6 months than never smokers [45]. In 
an early SpA cohort (DESIR; 68% ASAS criteria), current smokers had 66% lower odds of ASDAS 
inactive disease (<1.3) at 2 years [51]. Current smokers had 95% lower odds of ASDAS inactive 
disease at 3 years when restricting the DESIR cohort to peripheral SpA (ASAS criteria) [52]. Using the 
Swiss Clinical Quality Management Cohort (SCQM), Ciurea et al reported current smokers with axSpA 
to have 46% lower odds of BASDAI50 at 1 year [57]. 
 
In contrast to the large effect sizes above, all studies (4 axSpA, 0 PsA) using change in continuous 
outcomes found no clinically or statistically significant differences according to smoking status 
[41,57,59,60]; that is, although smokers had more severe disease at TNFi initiation than non-smokers, 
they experience the same absolute reduction in disease outcomes over time. In the same SCQM 
study by Ciurea et al, difference in BASDAI change over time (∆BASDAI) was not clinically or 
statistically significant, despite current smokers having less than half the odds of BASDAI50 [57]; a 
similar contrast was observed by Lord et al for ever/never smokers [41]. Ciurea et al did find 
statistically significant differences between current and never smokers in the subgroup with elevated 
baseline CRP (by 0.75 units in BASDAI and 0.69 units in ASDAS) [57]. This stratification is difficult to 
interpret since 1) policy makers are unlikely to implement targeted smoking cessation only in 
patients with elevated CRP, and 2) both axSpA disease activity and smoking are causes of elevated 
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CRP. The latter has potential to generate spurious findings, as suggested by ∆BASDAI between ever vs 
never smokers being twice as large as current vs never smokers, among the remaining patients with 
normal baseline CRP (i.e., opposite of biologic gradient and results for the subgroup with elevated 
CRP). 
 
Discrepancies between continuous and binary responses may be due to methodological differences 
[60]. Since smokers have more severe disease at baseline, fewer of them would meet a binary 
definition of response even if improvement were identical across all patients: if all patient improved 
by 3 BASDAI units in the BSRBR-AS, 40% of never smokers would achieve BASDAI50 response 
compared to 28% current smokers [60]. All individuals with high starting disease activity (whether 
they are smokers or grouped according to any other exposure) will be less likely to reach remission 
(or similar binary response definition), since they need to achieve a greater absolute improvement. 
 
What about treatment discontinuation? Current smoking (vs non-current) was not associated with 
TNFi discontinuation (HRadj 0.92; 95%CI 0.66 to 1.28) in another SCQM study focusing on BMI in 
axSpA [47]. Three other axSpA studies also did not demonstrate an effect of smoking on treatment 
discontinuation [48,49,61]. In the DANBIO register, however, current smokers with axSpA (HRadj 1.41 
[58]) and PsA (HRadj 1.20 [58]) had higher risk of TNFi discontinuation than non-smokers, but they did 
not account for relevant confounders. This study (like many others) did not adjust for baseline 
differences in disease activity on the premise that they were ‘intermediate variables’ (i.e., smoking → 
high baseline disease activity → treatment response); adjusting for mediators would indeed be 
inappropriate. However, this approach relies on the assumption that smoking causes high baseline 
disease activity, and not the converse. It is possible that patients smoking behavior is influenced by 
their symptoms. 
 
In a qualitative study of barriers to smoking cessation, Aimer et al found that many RA patients 1) 
used a smoking to distract from or help with pain; 2) were unable to move/exercise so they smoked 
instead; 3) used smoking as a coping mechanism [4]. Could disease activity drive smoking behavior 
more so than the converse? Here are some insightful quotes from their paper [4]: “You know 
10 
 
smoking honestly does seem the only thing I can do”; “It's something to do with your hands when 
you don't feel like doing anything.” These insights may explain why cross-sectional associations were 
not replicated in longitudinal studies. They also highlight the need to test assumptions often invoked 
in longitudinal analyses. 
 
When a smoker with axSpA is started on treatment, it is fair to assume that s/he will be less likely to 
achieve many binary definitions of response. But is this caused by smoking or confounding factors? 
The independent association between smoking and response is likely small or absent when relevant 
confounders are considered. The same patient in a parallel universe - with the same socioeconomic 
status, lifestyle, baseline disease severity etc – but who does not smoke, will be equally unlikely to 
respond. There is currently insufficient evidence to support targeted smoking cessation with the 
primary aim of improving the cost-effectiveness of biologic treatment. That is not to take away from 
the importance of smoking cessation. Smokers have worse disease before starting on treatment; 
therefore smoking may contribute to disease evolution up to that point. Cessation may help reduce 
functional decline; longitudinal change in HAQ was poorer in smokers with axSpA [43] and PsA [53]. 
Boonen et al found higher absenteeism in current smokers over 2 years (although not withdrawal 
from work or presenteeism) [44]. Randomised controlled trials are needed. To date, only 2 trials have 
been completed for smoking cessation in inflammatory arthritis (both in RA), neither measured 
disease activity [63]. 
 
Smoking vs radiographic progression 
 
Disease modification in inflammatory arthritis is underpinned by reduction in radiographic 
progression. One PsA and 17 axSpA studies of radiographic progression were found through 
literature search ([14,64–80] summarized in Supplementary Table S3). Most axSpA studies examined 
spinal progression, as change in mSASSS (modified Stoke AS Spinal Score) and new syndesmophyte 
formation. Results were unsuitable for meta-analysis. Only 3 of the 14 studies reported significant 
associations between smoking and radiographic progression. The most commonly cited is the 2012 
paper by Poddubnyy et al [68], where current smoking (along with baseline damage and elevated 
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CRP) predicted radiographic progression (increase of ≥2 mSASSS units over 2 years) in 210 mostly 
non-TNFi treated axSpA patients. Current smokers had over twice the odds of progression than 
non-current smokers in 4 models (ORadj 2.3 to 2.5; P=0.04 to 0.06) that also included classification 
(AS vs nr-axSpA), presence of syndesmophytes, sex and each of 4 representations of ESR/CRP. Using 
similar exposure/outcome definitions, Kim et al reported 3-times higher odds of progression in axSpA 
patients <50 years old, but these large effect sizes were not replicated in studies led by Min (ORadj 
1.04; 95%CI 0.57, 1.91), Braun (ORadj 0.97; 95%CI 0.54, 1.76) or Joo (ORadj 1.48; 95%CI 0.67, 3.27) 
[66,73,79]. Deminger et al also failed to find a significant effect over 5 years [76]; male ever smokers 
in this study had over 3 times the odds of progression, but effect sizes were reversed in females (i.e., 
smokers had lower odds of progression). Only 1 of the 3 studies examining pack year exposure found 
a significant association with ∆mSASSS [78]. None of the 4 studies of new syndesmophyte formation 
found statistically significant associations with smoking, although effect sizes were large in both 
directions (ORadj ranged from 0.64 to 2.43) [66,68,75,79].  
 
None of the above studies can tell us whether smoking is an independent predictor of radiographic 
progression (above the confounding effects of occupation, physical activity or other 
lifestyle/socioeconomic factors). Using a detailed dataset, Ramiro et al found that axSpA patients 
with physically demanding jobs had greater radiographic progression (2.2 vs 1.8 mSASSS units/2 
years) than those with less physical jobs [14]. The equivalent analysis for smoking was not significant 
(P=0.22). They also found that job type was numerically associated with mSASSS among smokers 
(progression 1.5 vs 1.2 mSASSS units/2 years). Taken together, these findings suggest that occupation, 
rather than smoking, may be a more important causal candidate for radiographic progression. The 
sole study of radiographic progression in PsA found no association between ever smoking and 
scoring of progression in 42 joints; the authors did, however, find associations with high levels of 
occupation-related mechanical stress [80]. This is a more biologically plausible hypothesis, since 
mechanical stress is key to SpA pathophysiology [81].  
 
What about radiographic progression at the sacroiliac joint? Three studies were found through 
systematic searches. Using the same cohort as above, Poddubnyy et al did not find an association 
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between smoking and SIJ progression [69]. Dougados et al reported 3.3 fold higher odds (95%CI 1.0, 
11.5) of progressing from non-radiographic axSpA to AS after 2 years [65] – an effect that became 
attenuated and non-significant after 5 years (ORadj 1.40 for HLA-B27 positive, ORadj 0.97 for negative) 
[64]. Measurement error is problematic for sacroiliac joint grading and may mask any real effects. 
 
In summary, the role of smoking in radiographic progression in SpA is far from clear. Citation bias for 
positive associations may impede further, improved analysis of this interesting relationship. Future 
studies would benefit from examining confounding factors associated with mechanical stress in 
parallel. 
 
Smoking vs EAMs 
 
AxSpA is associated with increased risk of psoriasis (50% higher than age- and sex-matched controls), 
uveitis (16-fold higher) and IBD (3-fold higher) [82]. Only a few studies examined the association 
between smoking and EAMs. In a cross-sectional analysis of the BSRBR-AS, current (but not past) 
smokers had 48% increased risk of psoriasis [12], which is consistent with increased risk of psoriasis 
among smokers in the general population [23]. This risk should be emphasised to smokers since 
psoriasis has significant impact on body image, quality of life and mental health [83].  
 
The BSRBR-AS study also found current smokers to have 26% lower risk of uveitis compared to ex- or 
never smokers [12]. This is immediately counterintuitive since smoking is a risk for uveitis in the 
general population [84] and resembles the case discussed earlier: smoking increases the risk of PsA 
in the general population, but appears ‘protective’ of PsA among people with psoriasis. The PsA 
paradox has been solved using population level data [21] and is said to be a consequence of the 
analysis (conditioning on an intermediate, potentially collider, variable). Equivalent analyses remain 
outstanding for axSpA. (Note that smoking needs to be causally associated with axSpA - like it is with 
psoriasis - for this explanation to be used analogously.) It is not impossible for smoking to have a 
protective role, as is the case in ulcerative colitis and Behcet’s disease – both related to uveitis and 
SpA [85]. If smoking has a genuine protective effect for uveitis, then it should also protect against 
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recurrent attacks. This was not the case: among those with uveitis, the authors of the BSRBR-AS 
study found 33% increased risk of recurrent attacks in current vs never smokers; 76% increased risk 
in current vs never smokers on biologics [86]. Further delving into such subsamples runs the risk of 
introducing more bias, thus analyses using population level data are needed. 
 
In the BSRBR-AS analysis, ex-smokers (but not current smokers) also had non-significantly elevated 
risk of IBD (RR 1.34), although there was insufficient power to interrogate Crohn’s and ulcerative 
colitis separately [12]. Adding to the catalogue of paradoxes, the authors reported a small and 
non-significant reduced risk for peripheral arthritis (RR 0.89). This was supported by findings from 
the French DESIR cohort, where peripheral arthritis was significantly associated with non-smoking 
(OR 1.58; 95%CI 1.10 to 2.27) [87]. These findings are inconsistent with what we know about 
smoking being associated with increased risk of peripheral psoriasis-related arthritis. 
 
There are fewer studies in PsA. Like axSpA, PsA is also associated with higher risk of uveitis (RR 3.6) 
and Crohn’s disease (RR 3.0) than the general UK population [88]. This study found that current 
smokers had higher incidence of Crohn’s disease than non-current smokers (effect size unreported). 
More PsA studies are needed. 
 
How do we interpret these results? 
 
We highlighted several counterintuitive findings, such as smoking appearing protective of uveitis and 
peripheral arthritis. Smoking also appeared protective of disease and radiographic progression in 
some studies. Contradictions like these are not new in other areas of observational research: it is 
well-known that infants born to smokers have lower birth weight and higher mortality compared to 
non-smokers, yet maternal smoking appeared beneficial for infant mortality among infants with low 
birth weight [89]. Such paradoxical associations can emerge through inappropriate analyses (Figure 
1), even in the absence of any effect from smoking. Other potential instances where collider bias 
may explain paradoxes in the rheumatology literature are reviewed in reference [90]. Although 
tempting to summon collider bias for every counterintuitive finding, we concede that it may not be 
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the only explanation [60]; this bias does, however, highlight the need for better designed 
observational research in population studies. Recommendations to reduce bias and improve design 





Figure 1. Collider bias. Imagine there is a disease that has only two causes: an environmental 
factor and a genetic factor. Imagine also that these two factors are completely unrelated in the 
general population (left panel). If we only study patients with this disease, an artefactual 
association will emerge between the two factors (right panel). If a patient does not have the 
gene, then the environmental factor must have caused the disease. Conversely, if a patient has 
never been exposed to the environmental factor, then it must have been the genetic factor that 
caused the disease. An inverse relationship is thus observed by conditioning on (or selecting, 
stratifying, “adjusting” using) a variable that has two common causes, i.e., a ‘collider’. We 
recommend reference [93] for a comprehensive introduction to these topics. 
 
 
We often talk about smoking as a ‘modifiable risk factor’ in the same breath as calling it a ‘predictor.’ 
The former calls for examination of its potential causal role and is distinct from the latter [94]; even 
great predictors may not necessarily be a cause. Recall that Sir Bradford Hill recommended criteria in 
addition to strength of association, among which are: consistency, biological gradient (i.e., 
dose-response) and specificity (i.e., not due to another factor). None of these are confirmed by 
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existing axSpA evidence. We reiterate smoking’s association with manual occupations, BMI, lower 
educational attainment, and other lifestyle and socioeconomic factors [2,12–15], which are seldom 
adequately considered. Causation is also supported by temporality (i.e, cause before effect): Insights 
from Aimer and colleagues’ qualitative study in RA highlight the possibility that disease activity 
influences smoking behaviour. Reverse causation is not implausible: alcohol was observed to 
‘improve’ symptoms of rheumatic disease [13,95], but evidence is emerging that it is instead high 




Smoking is a major cause of morbidity and mortality worldwide. It is associated with increased risk of 
psoriasis in axSpA and possibly also uveitis flares and IBD. EAMs, particularly when severe, can 
significantly impact quality of life and many other outcomes; therefore, risks should be highlighted 
to patients who continue to smoke. Smoking also increases risk of psoriatic arthritis. More studies 
are needed to examine the effect of smoking on longitudinal PsA outcomes and EAMs. Further 
research is also needed on whether counterintuitive associations between smoking and 
uveitis/arthritis arose from biological or methodological phenomena. Regardless of inconsistencies 
in existing evidence, we should support patients and encourage smoking cessation at every 
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